01.02.2011 • News

Pall's Eric Krasnoff Retirement Plans Could Set Stage for Sale of the Company

Pall CEO Eric Krasnoff
Pall CEO Eric Krasnoff

Shares of Pall Corp surged 11% on Monday after an analyst said the looming retirement of the diversified U.S. manufacturer's chief executive officer could set the stage for a sale of the company.

Pall, which makes filters used in manufacturing and healthcare applications, said after the close of trading on Friday that CEO Eric Krasnoff planned to retire on or before March 2012.

"We believe Eric Krasnoff's retirement is a catalyst for the company to merge or become acquired," Credit Suisse analyst Hamzah Mazari wrote in a note to clients. "The majority of Pall's closest competitors have been acquired by larger companies."

Pall shares were up $5.35 at $54.01 in morning trading on the New York Stock Exchange. Earlier, they had set a lifetime high of $54.96.

At Friday's close, the stock had risen almost 40% over the past year, outpacing a 29% rise for the Standard & Poor's capital goods industry index.

Krasnoff plans to pursue a personal relationship with Sandra Marino, who stepped down as Port Washington, New York-based Pall's general counsel when the two informed the board of their plans, the company said. Krasnoff, who is also chairman and president, will be 60 in March 2012 and could step down earlier if a successor is named before then.

Pall said in a statement that a board investigation into the matter found that the relationship had no effect on the company's results and that no company assets had been misused.

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.